News | August 10, 2009

HCSC Expands Pharmacy Adherence Program for Cholesterol-Lowering Drugs

August 10, 2009 – Health Care Service Corp. (HCSC), which operates the Blue Cross and Blue Shield plans in Illinois, New Mexico, Oklahoma and Texas, is expanding a successful new cholesterol medication adherence program that provides physicians with greater insight into their patients’ medication use.

The pharmacy adherence program has proven to increase the use of cholesterol medication by 25 percent for those not following their doctor’s orders, the company said. As the country’s largest customer-owned health insurer with 12.4 million members, HCSC wants the program to serve as a model for the healthcare system.

“By not taking cholesterol medications, many people are subjecting themselves to serious cardiovascular complications that could otherwise be prevented,” says Fawwaz M. Shoukfeh, M.D., a physician in Texas who sees great benefit from the program. “This allows us to better communicate with our patients, improve their health, and ultimately help reduce the cost of their care.”

Originally designed with its pharmacy benefits manager, Prime Therapeutics, the program allows HCSC to analyze pharmaceutical data to identify members not refilling their prescribed cholesterol medications. The company then notifies the patients and their physicians, who also receive a customized patient report that includes lab results, drug quantities filled, dispensed dates and refill due dates. Members of Blue Cross and Blue Shield of Texas have used the program since last year.

“In addition to increasing statin medication use, the program also can save money for our customers and members,” said Kevin Slavik, senior pharmacy director at HCSC. “Through a pharmacy benefit step therapy plan, we are able to encourage the use of generic medications.”

HCSC plans to expand the program to its other Blues plans in Illinois, New Mexico, Oklahoma this month. The program also will soon target diabetes and other conditions.

For more information: www.HCSC.com

Related Content

Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Overlay Init